bluebird bio, Inc. (NASDAQ:BLUE) has been assigned a $170.00 price target by research analysts at Maxim Group in a report released on Friday. The firm currently has a “buy” rating on the biotechnology company’s stock. Maxim Group’s price objective would indicate a potential upside of 4.17% from the stock’s previous close.

Several other equities research analysts also recently commented on BLUE. BidaskClub raised shares of bluebird bio from a “sell” rating to a “hold” rating in a research report on Wednesday, August 9th. Morgan Stanley reissued a “hold” rating on shares of bluebird bio in a research report on Wednesday, August 9th. Leerink Swann reissued an “outperform” rating and set a $120.00 target price on shares of bluebird bio in a research report on Saturday, September 30th. Jefferies Group LLC reissued a “buy” rating and set a $88.00 target price on shares of bluebird bio in a research report on Friday, August 11th. Finally, BMO Capital Markets reissued a “buy” rating and set a $108.00 target price on shares of bluebird bio in a research report on Friday, August 4th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and fourteen have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $131.05.

Shares of bluebird bio (BLUE) opened at $163.20 on Friday. bluebird bio has a 52 week low of $56.80 and a 52 week high of $164.80.

bluebird bio (NASDAQ:BLUE) last posted its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported ($1.73) earnings per share for the quarter, missing the consensus estimate of ($1.68) by ($0.05). bluebird bio had a negative net margin of 883.18% and a negative return on equity of 28.79%. The company had revenue of $7.71 million during the quarter, compared to the consensus estimate of $8.47 million. During the same period last year, the firm posted ($2.07) earnings per share. The company’s revenue for the quarter was up 397.4% on a year-over-year basis. equities research analysts forecast that bluebird bio will post -6.68 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This story was first reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this story on another site, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The original version of this story can be viewed at https://theolympiareport.com/2017/11/19/bluebird-bio-inc-blue-pt-set-at-170-00-by-maxim-group.html.

In other news, insider Nick Leschly sold 25,667 shares of the stock in a transaction on Wednesday, August 30th. The shares were sold at an average price of $115.18, for a total value of $2,956,325.06. Following the transaction, the insider now owns 339,368 shares of the company’s stock, valued at approximately $39,088,406.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Jeffrey T. Walsh sold 9,900 shares of the stock in a transaction on Friday, November 10th. The stock was sold at an average price of $149.58, for a total transaction of $1,480,842.00. Following the completion of the transaction, the insider now directly owns 28,798 shares in the company, valued at approximately $4,307,604.84. The disclosure for this sale can be found here. Insiders have sold a total of 193,168 shares of company stock worth $25,558,003 in the last ninety days. 3.90% of the stock is currently owned by insiders.

Several large investors have recently modified their holdings of the company. FMR LLC increased its holdings in shares of bluebird bio by 9.6% in the 2nd quarter. FMR LLC now owns 6,713,949 shares of the biotechnology company’s stock worth $705,301,000 after buying an additional 587,236 shares during the last quarter. Capital Research Global Investors grew its holdings in shares of bluebird bio by 9.9% during the 2nd quarter. Capital Research Global Investors now owns 5,483,117 shares of the biotechnology company’s stock valued at $576,001,000 after purchasing an additional 493,072 shares during the last quarter. Baillie Gifford & Co. grew its holdings in shares of bluebird bio by 3.8% during the 2nd quarter. Baillie Gifford & Co. now owns 5,400,658 shares of the biotechnology company’s stock valued at $567,339,000 after purchasing an additional 196,025 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of bluebird bio by 10.7% during the 2nd quarter. Vanguard Group Inc. now owns 3,559,102 shares of the biotechnology company’s stock valued at $373,884,000 after purchasing an additional 343,856 shares during the last quarter. Finally, BlackRock Inc. grew its holdings in shares of bluebird bio by 4.3% during the 2nd quarter. BlackRock Inc. now owns 3,320,329 shares of the biotechnology company’s stock valued at $348,801,000 after purchasing an additional 138,141 shares during the last quarter.

bluebird bio Company Profile

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Analyst Recommendations for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.